<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="145161">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01210924</url>
  </required_header>
  <id_info>
    <org_study_id>Pediatric treatment 2010</org_study_id>
    <secondary_id>2008ZX10001-007</secondary_id>
    <nct_id>NCT01210924</nct_id>
  </id_info>
  <brief_title>Chinese Network of Pediatric Antiretroviral Therapy</brief_title>
  <acronym>CN-PART</acronym>
  <official_title>Chinese Study of Pediatric Antiretroviral Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Center for AIDS/STD Control and Prevention, China CDC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Center for AIDS/STD Control and Prevention, China CDC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational cohort in pediatric HIV patients in China. Children who receive
      antiretroviral drugs will be recruited in this study. The main objectives are as follows: 1.
      To establish simpler and smarter pediatric antiretroviral therapy in China including both
      first-line and second-line regimens. 2. To study the nature, characteristics and mechanisms
      of immunoreconstitution in HIV-infected children using the data and samples from the
      pediatric antiretroviral therapy cohort. 3. To establish a basic science and clinical
      research network based on the pediatric antiretroviral cohort.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2010</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Acquired Immunodeficiency Syndrome</condition>
  <arm_group>
    <arm_group_label>Pediatric ART patients</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plamsa, PMBC, whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pediatric HIV-infected patients receiving triple antiretroviral drugs
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  clinical diagnosis of HIV infection

          -  receiving triple antiretroviral drugs

        Exclusion Criteria:

          -  clinical status not stable
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fujie Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Center for AIDS/STD control and prevention</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fujie Zhang, MD</last_name>
    <phone>+861063039086</phone>
    <email>treatment@chinaaids.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yan Zhao, MD</last_name>
    <phone>+861063039075</phone>
    <email>zhaoyanmgl@yahoo.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Center for AIDS/STD Control and Prevention, China Center for Disease Control and Prevention</name>
      <address>
        <city>Beijing</city>
        <zip>102206</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan Zhao, MD</last_name>
      <phone>+861063039075</phone>
      <email>zhaoyanmgl@yahoo.com.cn</email>
    </contact>
    <investigator>
      <last_name>Fujie Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 20, 2013</lastchanged_date>
  <firstreceived_date>September 27, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>children</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>antiretroviral therapy</keyword>
  <keyword>China</keyword>
  <keyword>Mortality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
